MDxHealth AssureMDx for Bladder Cancer Liquid Biopsy Test
MDxHealth has launched its AssureMDx for Bladder Cancer liquid biopsy test in the US as a laboratory-developed test. AssureMDx is a non-invasive, urine-based test. It searches for methylation and mutation biomarkers in order to assess the risk of bladder cancer for patients diagnosed with hematuria. The test's 93 percent sensitivity and 85 percent specificity can help doctors identify patients at increased risk for bladder cancer, who may benefit from cystoscopy, the company said. Testing will be conducted at MDxHealth's CAP- and CLIA-accredited lab in Irvine, California.